Innate Pharma
Presencia
Innate Pharma es una de las ...
Innate Pharma es una empresa que cotiza bajo el símbolo de cotización IPH (FR).
Ejecutivos
Ver el organigrama con sus 19 ejecutivos principales
Biografías más buscadas en Innate Pharma
- Herve Brailly, Interim Chief Executive Officer
- Irina Staatz-Granzer, Chairman of the Board
- Gilles Brisson, Member of the Supervisory Board
Recientes movimientos de ejecutivos en Innate Pharma
- Arvind Sood, se ha incorporado a la empresa como Executive Vice President and President of US Operations (noticia publicada el 4 de enero de 2024).
- Yannis Morel que ha sido Executive Vice President, Product Portfolio Strategy & Business Development and Member of the Executive Board, ha ascendido a Executive Vice President and Chief Operating Officer (noticia publicada el 4 de enero de 2024).
- Irina Staatz-Granzer que ha sido Vice-Chairman of the Supervisory Board, ha ascendido a Chairman of the Board (noticia publicada el 19 de diciembre de 2023).
Haga clic aquí para ver otros movimientos en Innate Pharma
Crear su alerta
para seguir los movimientos de los ejecutivos en Innate Pharma.
Farmacia
Innate Pharma tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Innate Pharma
- Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579/IPH6101 progressing to Phase 2 for blood cancer patients | Innate Pharma
- Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024 | Innate Pharma
- Innate Pharma announces its participation in upcoming Investor Conference | Innate Pharma
- Innate Pharma files its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F | Innate Pharma
- Innate Pharma presents at AACR 2024 preclinical efficacy of its pre-IND drug candidate IPH45, a novel Nectin-4 Antibody Drug Conjugate | Innate Pharma
- All press releases | Innate Pharma
- Innate Pharma reports Full Year 2023 financial results and business update | Innate Pharma
- Innate Pharma announces its participation to upcoming investor conference | Innate Pharma
- Innate Pharma announces conference call and webcast for Full Year 2023 financial results | Innate Pharma
- Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024 | Innate Pharma
- View more press releases Close
Redes sociales sobre Innate Pharma
- Innate Pharma en Wikipedia, Google News y Yahoo Finance
- Innate Pharma en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Herve Brailly 
Llame a Innate Pharma al +33 43...
